The Australian government signs an agreement with Merck Sharp & Dohme to buy 300,000 courses of the antiviral drug molnupiravir, pending regulator clearance, which would be the first pill to treat COVID-19 patients.
The Australian government signs an agreement with Merck Sharp & Dohme to buy 300,000 courses of promising antiviral drug molnupiravir, if cleared by regulators, which would be the first pill to treat COVID-19 patients.
The Australian government signs an agreement with Merck Sharp & Dohme to buy 300,000 courses of the antiviral drug molnupiravir, pending regulatorclearance, which would be the first pill to treat COVID-19 patients.
